Benzinga | Jul 22, 2020 07:09AM EDT

Akcea Announces Approval For Reimbursement Of TEGSEDI In Austria For Treatment Of Hereditary Transthyretin Amyloidosis With Polyneuropathy

BOSTON, July 22, 2020 /PRNewswire/ --Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that the Main Association of Austrian Social Security Institutions (Dachverband der ?sterreichischen Sozialversicherungstr?ger, or DV) has granted approval for the national reimbursement of TEGSEDI(r) (inotersen) for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin (hATTR) amyloidosis.